LINC00910: A Potential Drug Target and Biomarker (G100130581)

Target Name: LINC00910

NCBI ID: G100130581

LINC00910

Other Name(s): Long intergenic non-protein coding RNA 910, transcript variant 2 | long intergenic non-protein coding RNA 910

LINC00910: A Potential Drug Target and Biomarker

LINC00910 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker. It is a key regulator of the cell-cycle and has been shown to play a role in a variety of cellular processes, including cell growth, apoptosis, and tissue development. LINC00910 is also known as CDK4 kinase, and it is a key regulator of the cell-cycle at the G1 phase.

The drug target potential of LINC00910 is due to its unique structure and biology. It is a small molecule that can interact with multiple protein molecules, including the transcription factor p21 (also known as CDK4), which plays a critical role in regulating the cell-cycle. LINC00910 has been shown to interact with p21 and to inhibit its activity, which could lead to the inhibition of the cell-cycle and the inhibition of cell growth.

The biomarker potential of LINC00910 is due to its ability to be used as a therapeutic agent. LINC00910 has been shown to be downregulated in a variety of cancer types, including breast cancer, and it has been shown to have anti-cancer effects. Additionally, LINC00910 has also been shown to have anti-inflammatory effects and to have a positive impact on inflammation-related diseases.

The discovery and characterization of LINC00910 as a potential drug target and biomarker has important implications for the development of new cancer therapies. It provides a new target for cancer researchers to investigate and it can be used to develop new drugs, which can be effective in treating a variety of diseases.

Conclusion

In conclusion, LINC00910 is a promising drug target and biomarker. Its unique structure and biology, as well as its ability to interact with multiple protein molecules, make it an attractive target for cancer researchers. The inhibition of p21 activity by LINC00910 has the potential to slow down the cell-cycle and inhibit cell growth, which could be useful in treating a variety of cancer types. Additionally, LINC00910 has also been shown to have anti-inflammatory effects and to have a positive impact on inflammation-related diseases, which could be useful in treating a variety of diseases. Further research is needed to fully understand the potential of LINC00910 as a drug target and biomarker.

Protein Name: Long Intergenic Non-protein Coding RNA 910

The "LINC00910 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LINC00910 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.tech.

More Common Targets